• 1
    Des Jarlais D. C., McKnight C., Goldblatt C., Purchase D. Doing harm reduction better: syringe exchange in the United States. Addiction 2009; Epub ahead of print 10 February. DOI: 10.1111/j.1360-0443.2008.02465.x.
  • 2
    Wodak A., Cooney A. Do needle syringe programs reduce HIV infection among injecting drug users: a comprehensive review of the international evidence. Subst Use Misuse 2006; 41: 777813.
  • 3
    Friedman S. R., Cooper H. L., Tempalski B., Keem M., Friedman R., Flom P. L. et al. Relationships of deterrence and law enforcement to drug-related harms among drug injectors in US metropolitan areas. AIDS 2006; 20: 939.
  • 4
    Centers for Disease Control (CDC). HIV/AIDS Surveillance Report 2006. Vol. 18. Atlanta, GA: US Department of Health and Human Services, CDC; 2008.
  • 5
    Des Jarlais D. C., Perlis T., Arasteh K., Torian L. V., Hagan H., BeatriceS. et al. Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990–2001. AIDS 2005; 19(Suppl): S205.
  • 6
    Van Den Berg C., Smit C., Van Brussel G., Coutinho R., Prins M. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction 2007; 102: 145462.
  • 7
    Woody G. E., Kane V., Lewis K., Thompson R. Premature deaths after discharge from methadone maintenance: a replication. J Addict Med 2007; 1: 1805.
  • 8
    Gowing L., Farrell M., Bornemann R., Sullivan L. E., Ali R. Substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database of Systematic Reviews 2008, Issue 2. Art. No.: CD004145. DOI: 10.1002/14651858.CD004145.pub3.
  • 9
    Bouhnik A. D., Carrieri M. P., Rey D., Spire B., Gastaut J. A., GallaisH. et al. Drug injection cessation among HIV-infected injecting drug users. Addict Behav 2004; 29: 118997.
  • 10
    Smit C., Lindenburg K., Geskus R. B., Brinkman K., Coutinho R. A., Prins M. Highly active antiretroviral therapy (HAART) among HIV-infected drug users: a prospective cohort study of sexual risk and injecting behaviour. Addiction 2006; 101: 43340.
  • 11
    Crepaz N., Hart T. A., Marks G. Highly active antiretroviral therapy and sexual risk behavior: a meta-analytic review. JAMA 2004; 292: 22436.
  • 12
    Castilla J., Del Romero J., Hernando V., Marincovich B., Garcia S., Rodriguez C. Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J Acquir Immune Defic Syndr 2005; 40: 96101.
  • 13
    Emmanuelli J., Desenclos J. C. Harm reduction interventions, behaviours and associated health outcomes in France, 1996–2003. Addiction 2005; 100: 1690700.
  • 14
    Moatti J. P., Vlahov D., Feroni I., Perrin V., Obadia Y. Multiple access to sterile syringes for injection drug users: vending machines, needle exchange programs and legal pharmacy sales in Marseille, France. Eur Addict Res 2001; 7: 405.
  • 15
    Carrieri M. P., Amass L., Lucas G. M., Vlahov D., Wodak A., Woody G. E. Buprenorphine use: the international experience. Clin Infect Dis 2006; 43: S197215.
  • 16
    Jauffret-Roustide M., Couturier E., Le Strat Y., Barin F., Emmanuelli J., Semaille C. et al. Assessment of HIV and HCV seroprevalence and drug-users profiles, InVS-ANRS Coquelicot Study, France, 2004. Bull Epidemiol Hebd 2006; 33: 2447.
  • 17
    Obadia Y., Perrin V., Feroni I., Vlahov D., Moatti J. P. Injecting misuse of buprenorphine among French drug users. Addiction 2001; 96: 26772.
  • 18
    Roux P., Villes V., Blanche J., Bry D., Spire B., Feroni I. et al. Buprenorphine in primary care: risk factors for treatment injection and implications for clinical management. Drug Alcohol Depend 2008; 97: 10513.
  • 19
    Cazein F., Pillonel J., Le Strat Y., Loi F., Pinget R., David D. et al. Surveillance de l'infection à VIH-sida en France, 2007. Bull Epidemiol Hebd 2008; 45–46: 43442.